Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 25.56M | 24.54M | 23.40M | 21.68M | 20.13M |
| Total Depreciation and Amortization | 737.10K | 726.60K | 711.40K | 665.30K | 622.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.34M | -994.90K | 4.39M | 6.89M | 9.39M |
| Change in Net Operating Assets | -4.24M | -4.24M | -4.24M | -3.19M | -2.17M |
| Cash from Operations | 15.72M | 20.03M | 24.26M | 26.05M | 27.97M |
| Capital Expenditure | -219.10K | -1.93M | -3.64M | -3.76M | -3.89M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -28.18M | -21.91M | -15.39M | -14.17M | -13.03M |
| Cash from Investing | -28.40M | -23.84M | -19.03M | -17.94M | -16.92M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -370.00K | -358.60K | -347.20K | -302.70K | -258.20K |
| Issuance of Common Stock | 4.16M | 4.16M | 4.16M | 2.08M | -- |
| Repurchase of Common Stock | -5.16M | -5.04M | -4.91M | -2.45M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.65M | -1.64M | -1.61M | -1.61M | -1.61M |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.56M | -2.46M | -2.34M | -2.06M | -1.78M |
| Foreign Exchange rate Adjustments | 713.40K | -9.50K | -746.70K | -320.70K | 112.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.53M | -6.28M | 2.14M | 5.73M | 9.37M |